Back grey_arrow_rt.gif
 
Archived NATAP Articles from July 2003
 
null.gif
 
 
  1. Viral Response to Peginterferon plus Ribavirin in Co-infection - (7/24/03)

  2.  
  3. Antiretrovirals in First Line regimens: Trizivir, Sustiva, quad vs Triple therapy, Induction-Maintenance Reported by Dr Graeme Moyle, Chelsea & Westminster Hospital, London. - (7/24/03)

  4.  
  5. Efavirenz (EFV) Well Tolerated: IAS Report - (7/24/03)

  6.  
  7. IAS - Efavirenz (EFV) Well Tolerated: IAS Report Reported by Judith Aberg, MD , Washington University, St Louis, Missouri and the ACTG - (7/23/03)

  8.  
  9. IAS - Recombinant Human Growth Hormone (r-hGH) Reported by Judith Aberg, MD , Washington University, St Louis, Missouri and the ACTG - (7/22/03)

  10.  
  11. IAS - 10% Rate of HIV Drug Resistance in Newly Infected: genotype resistance testing suggested for newly infected - (7/21/03)

  12.  
  13. IAS - Tenofovir: methadone & ribavirin interaction studies, and renal toxicity in 2 cases - (7/21/03)

  14.  
  15. IAS - Trizivir-Efavirenz Induction-Maintenance Study - (7/21/03)

  16.  
  17. IAS - Kaletra Update: Kaletra+Tenofovir+3TC Once Daily Study; Updated PHHS Guidelines on Preferred Regimens for First-Line Therapy - (7/21/03)

  18.  
  19. PHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents PDF - (7/21/03)

  20.  
  21. New HIV Treatment Guidelines Focus on "Preferred" Regimens PDF
    07/18/03

  22. IAS - Fuzeon Story: new 48 week study results; 24-week results hold up at week 48 - (7/17/03)

  23.  
  24. IAS - Does Early HCV Kinetics Predict Response to Peginterferon and Ribavirin HCV Therapy among HIV Co-infected Individuals - (7/17/03)

  25.  
  26. IAS - Reyataz+ritonavir vs Kaletra in treatment-experienced - (7/16/03)

  27.  
  28. IAS - SPD754: new NRTI, early study results - (7/16/03)

  29.  
  30. IAS - FTC: 60 week study results - (7/16/03)

  31.  
  32. IAS - Fuzeon (T-20) Story - (7/15/03)

  33.  
  34. IAS - ABC/AZT/3TC vs Efavirenz Based Regimens: ACTG 5095 - (7/14/03)

  35.  
  36. IAS - High Viral failure Rates with Abacavir/3TC/Tenofovir Once Daily Regimen - (7/14/03)

  37.  
  38. Report from The 4th International Workshop on Clinical Pharmacology of HIV Therapy - (7/14/03)

  39.  
  40. STATE AIDS DIRECTORS, PHARMACEUTICAL COMPANIES JOIN IN $50 MILLION PLAN TO ASSIST ADAPs - (7/10/03)

  41.  
  42. Lipo - Switch to Abacavir Improves Fat Loss; Experimental Uridine Study Improves Mitochondrial Toxicity in Vitro - (7/10/03)

  43.  
  44. Lipo - Atazanavir: Evaluation of Body Changes and Lipids/Glucose After 48 weeks Treatment - (7/10/03)

  45.  
  46. Lipo - Rosiglitazone For Lipoatrophy: mixed results - (7/9/03)

  47.  
  48. Lipodystrophy Workshop - (7/8/03)

  49.  
  50. EASL - COMBINATION OF PEGYLATED INTERFERON AND LAMIVUDINE IS SUPERIOR TO LAMIVUDINE MONOTHERAPY IN THE TREATMENT OF CHRONIC HEPATITIS B - A RANDOMIZED TRIAL - (7/7/03)

  51.  
  52. EASL - Pegasys News: 4 year follow-up; study of treating cirrhotics; study of Peg-Intron non-responders - (7/7/03)

  53.  
  54. EASL - Entecavir, new HBV drug, Suppresses Lamivudine Resistance - (7/7/03)

  55.  
  56. Hepatitis C virus infection and incident type 2 diabetes - (7/7/03)

  57.  
  58. HIV Infection-A Risk Factor for Osteoporosis - (7/7/03)

  59.  
  60. Bone Mass in HIV-Infected Patients: Focus on the Role of Therapy and Sex - (7/7/03)

  61.  
  62. Hepatitus C Therapeutic Vaccine: study data released - (7/7/03)

  63.  
  64. FDA Approves New HIV Drug FTC, emtricitabine - (7/3/03)

  65.  
  66. Reyataz (atazanavir) in These Pharmacies - (7/3/03)

  67.  
  68. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma - (7/3/03)

  69.  
  70. Hispanics & HIV Testing - (7/2/03)

  71.  
  72. HIV and African Americans & Hispanics & Women - (7/2/03)

  73.  
  74. Regulation of CC chemokine receptor 5 in Hepatitis G virus infection - (7/2/03)

  75.